Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20-positive B-cell Non-Hodgkin's Lymphoma”

Showing 4 of 0 results

Early research (Phase 1)UnknownNCT04215016
What this trial is testing

Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma

Who this might be right for
Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive
Fujian Medical University 18
Large-scale testing (Phase 3)Ended earlyNCT00486759
What this trial is testing

Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Who this might be right for
B-cell Lymphoma
Hoffmann-La Roche 787
Early research (Phase 1)Looking for participantsNCT06725524
What this trial is testing

JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma

Who this might be right for
B-cell Non Hodgkin Lymphoma
Shanghai JMT-Bio Inc. 186
Testing effectiveness (Phase 2)Study completedNCT00290667
What this trial is testing

Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Who this might be right for
Lymphoma
German High-Grade Non-Hodgkin's Lymphoma Study Group 586

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation